LataMed AI Corp. (OTC: LMED) announced that its mobile healthcare application has entered the final stage of development, with the company completing testing, optimization, and deployment preparation. The app is expected to be submitted for distribution and become available through the Apple App Store and Google Play in the coming weeks, subject to platform review and technical requirements.
This development represents a transition from application development to public availability, providing users with a primary mobile access point to the LataMed AI digital healthcare ecosystem. The app aims to offer a convenient interface for accessing supported healthcare services, digital tools, and additional functionality as the platform expands.
The company's development team is focused on final technical testing, interface optimization, platform compatibility review, and deployment-related preparations. Once available, the app is expected to serve as a scalable mobile foundation for introducing future healthcare-related features, including patient-facing tools, healthcare-provider interaction, digital communications, and access to medical and wellness information.
Mobile accessibility is particularly important to LataMed AI's strategy in Latin America, where smartphones are a primary means of accessing digital services. By launching on both major mobile marketplaces, the company intends to provide users with a direct and accessible way to interact with its developing healthcare ecosystem.
The app is also expected to support the company's longer-term strategy of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, and other participants in a more integrated digital healthcare environment. LataMed AI continues to develop its artificial intelligence-supported technologies, including CardioAI, PulmoAI, and NeuroAI, as part of its broader healthcare technology strategy.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated, "Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI. Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes."
Dr. Levy added, "Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools."
The company believes the anticipated release will represent another step in moving its technology from development into increasingly accessible, user-facing digital healthcare infrastructure. Following the initial release, LataMed AI intends to evaluate additional functionality, platform integrations, and user-facing tools for future versions.
The company expects to provide additional updates regarding submission, availability, and application functionality as milestones are completed. For more information, visit https://latamed.ai or review filings with the U.S. Securities and Exchange Commission at www.sec.gov.
